CAPLIPOINT Stock Overview
Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for CAPLIPOINT from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Caplin Point Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,311.45 |
| 52 Week High | ₹2,539.85 |
| 52 Week Low | ₹1,225.00 |
| Beta | 0.42 |
| 1 Month Change | 18.98% |
| 3 Month Change | 19.17% |
| 1 Year Change | 64.42% |
| 3 Year Change | 186.27% |
| 5 Year Change | 661.35% |
| Change since IPO | 6,356.56% |
Recent News & Updates
Investor Optimism Abounds Caplin Point Laboratories Limited (NSE:CAPLIPOINT) But Growth Is Lacking
Dec 01
₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results
Nov 10With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case
Oct 31Recent updates
Investor Optimism Abounds Caplin Point Laboratories Limited (NSE:CAPLIPOINT) But Growth Is Lacking
Dec 01₹2,142 - That's What Analysts Think Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Is Worth After These Results
Nov 10With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case
Oct 31Caplin Point Laboratories (NSE:CAPLIPOINT) Is Due To Pay A Dividend Of ₹2.50
Sep 12Earnings Update: Here's Why Analysts Just Lifted Their Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Price Target To ₹1,764
Aug 11Caplin Point Laboratories (NSE:CAPLIPOINT) Is Paying Out A Dividend Of ₹2.50
Aug 10Investors Aren't Buying Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Earnings
Jul 12Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues
May 24Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?
May 04Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement
Mar 07With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case
Oct 24Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise
Sep 15Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50
Aug 11We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise
Sep 23Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year
Sep 11Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?
Jul 22Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹2.00
May 15A Look At The Intrinsic Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
Jan 21Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?
Oct 20Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹1.50
Sep 17Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹1.50
Sep 03Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Intrinsic Value Is Potentially 28% Above Its Share Price
Aug 27Is Caplin Point Laboratories (NSE:CAPLIPOINT) A Risky Investment?
Jun 12Shareholder Returns
| CAPLIPOINT | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -5.5% | 0.8% | -4.2% |
| 1Y | 64.4% | 39.7% | 19.1% |
Return vs Industry: CAPLIPOINT exceeded the Indian Pharmaceuticals industry which returned 39.7% over the past year.
Return vs Market: CAPLIPOINT exceeded the Indian Market which returned 19.1% over the past year.
Price Volatility
| CAPLIPOINT volatility | |
|---|---|
| CAPLIPOINT Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: CAPLIPOINT has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: CAPLIPOINT's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 3,406 | Sridhar Ganesan | www.caplinpoint.net |
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry syrups, lyophilized vials, prefilled syringes, emulsion injection, and topicals.
Caplin Point Laboratories Limited Fundamentals Summary
| CAPLIPOINT fundamental statistics | |
|---|---|
| Market cap | ₹175.67b |
| Earnings (TTM) | ₹4.94b |
| Revenue (TTM) | ₹18.33b |
35.6x
P/E Ratio9.6x
P/S RatioIs CAPLIPOINT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CAPLIPOINT income statement (TTM) | |
|---|---|
| Revenue | ₹18.33b |
| Cost of Revenue | ₹7.88b |
| Gross Profit | ₹10.45b |
| Other Expenses | ₹5.52b |
| Earnings | ₹4.94b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 64.93 |
| Gross Margin | 57.02% |
| Net Profit Margin | 26.93% |
| Debt/Equity Ratio | 0.02% |
How did CAPLIPOINT perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield4%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 02:01 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Caplin Point Laboratories Limited is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |
| Kameswari V. S. Chavali | FirstCall Research |
| Siddhant Khandekar | ICICIdirect.com |